{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-105175","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2024-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.314258+00:00","generated_at":"2026-05-31T05:43:48.534527+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"enGene Q3 net loss $14.1M; cash $257.7M; LEGEND data expected Sept 2024","bullets":["Net loss $14.1M ($0.32/share) vs $6.0M prior year; operating expenses $16.8M (up from $6.2M).","Cash and equivalents $257.7M; expects runway into 2027.","Preliminary LEGEND study data (BCG-unresponsive NMIBC) due by end of September 2024.","Ron Cooper appointed CEO and board member; Dr. Raj Pruthi promoted to CMO in July 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-105175","json":"https://secwatch.observer/filing/0000950170-24-105175.json","markdown":"https://secwatch.observer/filing/0000950170-24-105175.md","text":"https://secwatch.observer/filing/0000950170-24-105175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024105175/0000950170-24-105175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024105175/engn-20240910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:43:48.534527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}